EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC-ND 4.0

Comparative Effectiveness of Metformin Versus Sulfonylureas on Exceptional Longevity in Women With Type 2 Diabetes: Target Trial Emulation

Aladdin H Shadyab, Mark A Espeland iD, Andrew O Odegaard, JoAnn E Manson, Bernhard Haring, Karen C Johnson iD, Zhao Chen iD, Bowei Zhang iD, Andrea Z LaCroix

The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences · 2025

DOI: 10.1093/gerona/glaf095 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 2025. Verfasst von Aladdin H Shadyab und 8 weiteren Autor:innen. Beteiligte Einrichtung: Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, California, USA. Hauptthemen laut MEDLINE: Metformin, Diabetes Mellitus, Type 2, Sulfonylurea Compounds, Hypoglycemic Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, WHI NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The association of metformin with mortality has been mixed, and no prior study has determined whether metformin initiation is associated with exceptional longevity, defined as survival to ages 90 and older.

Methods

We performed a new-user, active comparator cohort study using the target trial emulation framework among the Women’s Health Initiative cohort to determine whether metformin versus sulfonylurea initiation was associated with exceptional longevity (survival to age 90). We identified participants ≥60 years with incident type 2 diabetes and no history of hypoglycemic agents or insulin prior to treatment initiation to perform intention-to-treat analyses. We used 1:1 propensity score matching on demographic characteristics, lifestyle behaviors, diabetes duration, comorbidities (hypertension, cardiovascular disease, chronic obstructive pulmonary disease, and cancer), body mass index, and concomitant medications to balance treatment groups on key confounders.

Results

Among 438 propensity score-matched women with type 2 diabetes, the incidence rate of death before age 90 per 100 person-years in women initiating metformin monotherapy was 3.7 (95% CI: 3.1–4.4) compared with 5.0 (95% CI: 4.2–5.8) for sulfonylurea monotherapy. The adjusted risk of death before age 90 was 30% lower for initiation of metformin monotherapy versus sulfonylurea monotherapy (hazard ratio, 0.70; 95% CI: 0.56–0.88).

Conclusions

In this first target trial emulation of metformin and exceptional longevity, we found that metformin initiation increased exceptional longevity compared with sulfonylurea initiation among women with type 2 diabetes. Because this comparison was not made to placebo in a randomized controlled trial and given the observational design with potential for residual confounding, causality cannot be inferred.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminDiabetes Mellitus, Type 2Sulfonylurea CompoundsHypoglycemic AgentsLongevityHumansFemaleAgedMiddle AgedAged, 80 and overPropensity ScoreCohort Studies

Stichwörter der Autor:innen

GeroscienceGerotherapeuticHealthy agingMedication

Substanzen

MetforminSulfonylurea CompoundsHypoglycemic Agents

Autor:innen und Institutionen

  • Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, California, USA.
  • Division of Geriatrics, Gerontology, and Palliative Care, Department of Medicine, University of California, San Diego, La Jolla, California, USA.
  • Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
  • Department of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
  • Department of Epidemiology and Biostatistics, University of California Irvine, Irvine, California, USA.
  • Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Mark A Espeland, Karen C Johnson, Zhao Chen, Bowei Zhang

Förderung

  • NHLBI NIH HHS
  • WHI NIH HHS
  • NIH HHS
  • NIA NIH HHS
  • National Heart, Lung, and Blood Institute
  • National Institutes of Health
  • U.S. Department of Health and Human Services

Zitieren

APA

Shadyab, A. H., Espeland, M. A., Odegaard, A. O., Manson, J. E., Haring, B., Johnson, K. C., Chen, Z., Zhang, B., & LaCroix, A. Z. (2025). Comparative Effectiveness of Metformin Versus Sulfonylureas on Exceptional Longevity in Women With Type 2 Diabetes: Target Trial Emulation. The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences. https://doi.org/10.1093/gerona/glaf095

Vancouver

Shadyab AH, Espeland MA, Odegaard AO, Manson JE, Haring B, Johnson KC, et al. Comparative Effectiveness of Metformin Versus Sulfonylureas on Exceptional Longevity in Women With Type 2 Diabetes: Target Trial Emulation. The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences. 2025. doi:10.1093/gerona/glaf095

BibTeX
@article{Shadyab2025,
  author = {Shadyab, Aladdin H and Espeland, Mark A and Odegaard, Andrew O and Manson, JoAnn E and Haring, Bernhard and Johnson, Karen C and Chen, Zhao and Zhang, Bowei and LaCroix, Andrea Z},
  title = {Comparative Effectiveness of Metformin Versus Sulfonylureas on Exceptional Longevity in Women With Type 2 Diabetes: Target Trial Emulation},
  journal = {The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences},
  year = {2025},
  doi = {10.1093/gerona/glaf095}
}
Kostenlos starten →